Citi Reiterates Buy Rating on Immunovant (IMVT)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Immunovant (IMVT) PT Lowered to $33 at BofA Securities
March 19, 2025 2:59 PM EDTBofA Securities analyst Jason Gerberry lowered the price target on Immunovant (NASDAQ: IMVT) to $33.00 (from $38.00) while maintaining a Buy rating.... More
Roivant Sciences (ROIV) Announces Positive Results for Batoclimab Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy Studies
March 19, 2025 7:45 AM EDTImmunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study in CIDP.
We are excited to share positive results from our MG and CIDP studies. While neurologists and patients are very enthusiastic about currently approved FcRn inhibitors, they tell us that they also see a lot of potential for a next-generation FcRn inhibitor that can offer deeper and more... More
